image: A map of SNMMI's Radiopharmaceutical Therapy Centers of Excellence.
Credit: Image courtesy of SNMMI.
Reston, VA (October 2, 2024) — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has designated nearly 100 institutions as Radiopharmaceutical Therapy Centers of Excellence across the United States, its territories, and Canada. This designation, which identifies sites that attest that they meet strict regulatory, training, qualification, experience, and performance criteria, ensures reliable access for patients requiring radiopharmaceutical therapy and theranostics.
Twenty-four institutions have been designated as Registered Radiopharmaceutical Therapy Sites that administer at least one radiopharmaceutical therapy. An additional 24 sites received the Clinical Radiopharmaceutical Therapy Center designation, which signifies experience administering multiple radiopharmaceutical therapies and established care teams in specific disease areas. Forty-six institutions have been recognized as Comprehensive Radiopharmaceutical Therapy Centers: institutions that meet all the above requirements and actively participate in radiopharmaceutical therapy research.
“With the Radiopharmaceutical Therapy Centers of Excellence designation, institutions can assure patients, their families, referring physicians, and payors that rigorous procedures are in place and followed, ultimately leading to appropriate patient selection and outcomes from radiopharmaceutical therapy,” said Cathy Sue Cutler, PhD, FSNMMI, president of SNMMI.
The need to increase access to radiopharmaceutical therapy—specifically theranostics—was recently highlighted in a report from The Lancet Oncology Commission. As part of its call to action, the journal recommended the adoption of global standards for infrastructure and administration, as well as harmonization of clinical trials to advance research.
“With the Radiopharmaceutical Centers of Excellence program,” said Cutler, “SNMMI is laying the groundwork for institutions in other countries to implement successful radiopharmaceutical therapy centers. We encourage others around the world to adapt these guidelines to ensure high-quality radiopharmaceutical therapy centers in their countries.”
For more information about the SNMMI Radiopharmaceutical Therapy Center of Excellence, including an interactive map of institutions, visit https://snmmi.org/therapy.
Find an RPT COE near you.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.